CIK 0001761612
- Non-accelerated filer
- Smaller reporting company
BICYCLE THERAPEUTICS PLC
Sign in to watch- Ticker
- BCYC
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- United Kingdom
- Entity type
- Operating
- Phone
- +44 1223261503
- Business address
- BLOCKS A & B, PORTWAY BUILDING, GRANTA PARK, GREAT ABINGTON, CAMBRIDGE, United Kingdom, CB21 6GS
- Former names
- BICYCLE THERAPEUTICS Ltd
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $64,039
- in 7 filings, $7K under 10b5-1 plans
Net −$64,039. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
- Lee Kevin −$27K CHIEF EXECUTIVE OFFICER sold 1% of stake
- Swanton Robert Charles −$12K Director sold 18% of stake
- Skynner Michael −$9K CHIEF SCIENTIFIC OFFICER sold 2% of stake
- Perry Jennifer Scott −$7K Chief Operating Officer sold 2% of stake
- Hannay Michael Charles Ferguson −$6K CHIEF PROD & SUPPLY CHAIN OFF sold 2% of stake
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2024-07-03 | Keen Nicholas CHIEF SCIENTIFIC OFFICER | Sale | −779 | $19.64 | $15K | 62,024 |
| 2024-04-03 | Keen Nicholas CHIEF SCIENTIFIC OFFICER | Sale | −790 | $23.81 | $19K | 62,803 |
| 2024-01-03 | Keen Nicholas Chief Scientific Officer | Sale | −2,640 | $17.50 | $46K | 63,593 |
| 2024-01-02 | Keen Nicholas Chief Scientific Officer | Grant or award | +28,000 | 66,233 | ||
| 2024-01-02 | Keen Nicholas Chief Scientific Officer | Grant or award · Employee Stock Option (right to buy) | +56,000 | 56,000 | ||
| 2023-10-03 | Keen Nicholas Chief Scientific Officer | Sale | −272 | $20.00 | $5K | 38,233 |
| 2023-07-03 | Keen Nicholas Chief Scientific Officer | Sale | −336 | $25.10 | $8K | 38,505 |
| 2023-04-03 | Keen Nicholas Chief Scientific Officer | Sale | −319 | $21.11 | $7K | 38,841 |
| 2023-01-03 | Keen Nicholas Chief Scientific Officer | Grant or award | +17,500 | 40,977 | ||
| 2023-01-03 | Keen Nicholas Chief Scientific Officer | Sale | −1,817 | $29.06 | $53K | 39,160 |
| 2023-01-03 | Keen Nicholas Chief Scientific Officer | Grant or award · Employee Stock Option (right to buy) | +35,000 | 35,000 | ||
| 2022-01-03 | Keen Nicholas Chief Scientific Officer | Grant or award | +15,000 | 23,477 | ||
| 2022-01-03 | Keen Nicholas Chief Scientific Officer | Grant or award · Employee Stock Option (right to buy) | +30,000 | 30,000 | ||
| 2021-12-21 | Keen Nicholas Chief Scientific Officer | Exercise or conversion | +15,477 | $14.00 | $217K | 15,477 |
| 2021-12-21 | Keen Nicholas Chief Scientific Officer | Exercise or conversion · Stock Option (Right to Buy) | −15,477 | 161,927 | ||
| 2021-10-05 | Keen Nicholas Chief Scientific Officer | Sale | −2,178 | $45.10 | $98K | 0 |
| 2021-10-01 | Keen Nicholas Chief Scientific Officer | Sale | −1,188 | $45.00 | $53K | 2,178 |
| 2021-09-16 | Keen Nicholas Chief Scientific Officer | Sale | −1,955 | $45.01 | $88K | 3,366 |
| 2021-09-15 | Keen Nicholas Chief Scientific Officer | Sale | −3,000 | $45.00 | $135K | 5,321 |
| 2021-09-02 | Keen Nicholas Chief Scientific Officer | Sale | −10,000 | $40.00 | $400K | 8,321 |
Page 1 of 2 · 29 trades